169 related articles for article (PubMed ID: 14624914)
1. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG
Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
[TBL] [Abstract][Full Text] [Related]
7. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Kirby RS
Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Elhilali MM
Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
[TBL] [Abstract][Full Text] [Related]
9. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
10. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
[TBL] [Abstract][Full Text] [Related]
13. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
Ahtoy P; Chrétien P; Dupain T; Rauch C; Rouchouse A; Delfolie A
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):289-94. PubMed ID: 12139205
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ
Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
[TBL] [Abstract][Full Text] [Related]
18. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
[TBL] [Abstract][Full Text] [Related]
19. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
